Ferrari Shares Decline After Unveiling First Electric Vehicle Amid Market Skepticism Indian Rupee Rebounds Past 96 on Strong RBI Intervention Taiwan Chip Stocks Climb After Nvidias 150 Billion Spending Commitment US Seeks to Expand American AI Integration Across Asia After TrumpXi Engagement Retail Sales Post Solid Gain Yet Early Signals of Consumer Pullback Emerge Pope Leos Encyclical on AI Draws Ethical Lines as Anthropic Attends Signing LOAR Q1 2026 Earnings EPS Surges 1087 Above Estimates Stock Edges Lower FOXF Q1 2026 Earnings EPS Beats Estimates by 1153 Amid Cost Discipline NKE Q1 2026 Earnings Strong EPS Beat Amidst Uncertain Revenue Landscape Ascent Industries Co ACNT Q1 2025 Earnings Losses Widen as EPS Misses Estimates Sharply SCCE Q4 2025 Earnings EPS Surges Past Estimates on Solid Performance Newton Golf Q1 2026 Earnings Deeper Loss Than Expected as PreRevenue Company Navigates Development Phase Macys Inc M Holds Steady Near Support A Test of Resilience Ellington Credit Company EARN Bounces Modestly Support Holds Near 457 Twilio TWLO Slips 43 as Selling Pressure Intensifies Support at 172 in Focus Bank of the James Financial Group BOTJ Holds Steady with Modest Gains Amid Support Levels Proto Labs PRLB Holds Steady Near Support as Modest Gains Signal Consolidation Market Breadth Weakness May Keep Nifty RangeBound Sudeep Shah Shares Views on Amber Tata Comm and Other Stocks LYEL Q1 2026 Earnings Significant EPS Beat Driven by Operational Efficiency and Pipeline Progress The Hartford Insurance Group HIG Edges Lower Consolidation Within Established Technical Range SPMC Q1 2026 Earnings EPS Misses Estimates Despite Stock Rally SUPV Q1 2026 Earnings Massive EPS Beat as Company Swings to Profitability Hub Group Q3 2025 Earnings Slight EPS Miss Amid Mixed Freight Conditions Nephros Q1 2026 Earnings EPS Misses Estimates by a Hair Shares Edge Higher Aptiv PLC Q1 2026 Earnings Strong EPS Beat Driven by Operational Efficiency Butterfly Network BFLY Q1 2026 Earnings NarrowerthanExpected Loss Fuels Investor Caution Marker Therapeutics Q1 2026 Earnings NarrowerthanExpected Loss as Clinical Pipeline Progresses